TransCode Therapeutics, Inc. (RNAZ)
1.81
-0.08
(-4.23%)
USD |
NASDAQ |
Sep 09, 16:00
1.81
0.00 (0.00%)
After-Hours: 16:07
TransCode Therapeutics Enterprise Value : 160.23M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 160.23M |
| September 04, 2026 | 160.41M |
| September 03, 2026 | 160.50M |
| September 02, 2026 | 160.36M |
| September 01, 2026 | 160.41M |
| August 31, 2026 | 160.45M |
| August 28, 2026 | 160.53M |
| August 27, 2026 | 160.63M |
| August 26, 2026 | 160.69M |
| August 25, 2026 | 160.88M |
| August 24, 2026 | 161.05M |
| August 21, 2026 | 161.23M |
| August 20, 2026 | 161.33M |
| August 19, 2026 | 161.57M |
| August 18, 2026 | 161.60M |
| August 17, 2026 | 161.52M |
| August 14, 2026 | 161.64M |
| August 13, 2026 | 161.84M |
| August 12, 2026 | 161.73M |
| August 11, 2026 | 161.79M |
| August 10, 2026 | 162.25M |
| August 07, 2026 | 162.33M |
| August 06, 2026 | 162.64M |
| August 05, 2026 | 162.62M |
| August 04, 2026 | 162.82M |
| Date | Value |
|---|---|
| August 03, 2026 | 162.59M |
| July 31, 2026 | 162.94M |
| July 30, 2026 | 163.63M |
| July 29, 2026 | 163.34M |
| July 28, 2026 | 163.38M |
| July 27, 2026 | 163.84M |
| July 24, 2026 | 164.32M |
| July 23, 2026 | 165.66M |
| July 22, 2026 | 166.82M |
| July 21, 2026 | 166.82M |
| July 20, 2026 | 167.15M |
| July 17, 2026 | 166.85M |
| July 16, 2026 | 166.69M |
| July 15, 2026 | 167.12M |
| July 14, 2026 | 167.00M |
| July 13, 2026 | 166.98M |
| July 10, 2026 | 167.25M |
| July 09, 2026 | 168.03M |
| July 08, 2026 | 166.29M |
| July 07, 2026 | 166.86M |
| July 06, 2026 | 166.18M |
| July 02, 2026 | 167.03M |
| July 01, 2026 | 166.06M |
| June 30, 2026 | 164.60M |
| June 29, 2026 | 135.24M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 11.79B |
| Oncolytics Biotech, Inc. | 96.67M |
| Sangamo Therapeutics, Inc. | 58.40M |
| Sarepta Therapeutics, Inc. | 2.469B |
| Anixa Biosciences, Inc. | 83.62M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.750M |
| Total Expenses (Quarterly) | 6.750M |
| EPS Diluted (Quarterly) | -7.172 |
| Earnings Yield | -2.80K% |
| Normalized Earnings Yield | -2060.99 |